Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.
Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS. Pulley JM, et al. Among authors: zaleski nm. Target Oncol. 2018 Feb;13(1):61-68. doi: 10.1007/s11523-017-0542-1. Target Oncol. 2018. PMID: 29218624 Free PMC article. Review.
Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics.
Pulley JM, Shirey-Rice JK, Lavieri RR, Jerome RN, Zaleski NM, Aronoff DM, Bastarache L, Niu X, Holroyd KJ, Roden DM, Skaar EP, Niswender CM, Marnett LJ, Lindsley CW, Ekstrom LB, Bentley AR, Bernard GR, Hong CC, Denny JC. Pulley JM, et al. Among authors: zaleski nm. Assay Drug Dev Technol. 2017 Apr;15(3):113-119. doi: 10.1089/adt.2016.772. Epub 2017 Apr 5. Assay Drug Dev Technol. 2017. PMID: 28379727 Free PMC article.
When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.
Pulley JM, Jerome RN, Zaleski NM, Shirey-Rice JK, Pruijssers AJ, Lavieri RR, Chettiar SN, Naylor HM, Aronoff DM, Edwards DA, Niswender CM, Dugan LL, Crofford LJ, Bernard GR, Holroyd KJ. Pulley JM, et al. Among authors: zaleski nm. Assay Drug Dev Technol. 2017 Dec;15(8):354-361. doi: 10.1089/adt.2017.821. Epub 2017 Dec 1. Assay Drug Dev Technol. 2017. PMID: 29193979 Free PMC article.
Advocating for mutually beneficial access to shelved compounds.
Pulley JM, Jerome RN, Shirey-Rice JK, Zaleski NM, Naylor HM, Pruijssers AJ, Jackson JC, Bernard GR, Holroyd KJ. Pulley JM, et al. Among authors: zaleski nm. Future Med Chem. 2018 Jun 1;10(12):1395-1398. doi: 10.4155/fmc-2018-0090. Epub 2018 May 23. Future Med Chem. 2018. PMID: 29788759 No abstract available.
The PathLink Acquired Gestational Tissue Bank: Feasibility of Project PLACENTA.
Linder JE, Batey K, Johnston R, Cohen EM, Wang Y, Wang X, Zaleski NM, Rogers LM, McDonald WH, Reyzer ML, Judd A, Goldstein J, Correa H, Pulley J, Aronoff DM. Linder JE, et al. Among authors: zaleski nm. J Reprod Biotechnol Fertil. 2018;7:14-27. J Reprod Biotechnol Fertil. 2018. PMID: 30637122 Free PMC article.
Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data.
Pulley JM, Rhoads JP, Jerome RN, Challa AP, Erreger KB, Joly MM, Lavieri RR, Perry KE, Zaleski NM, Shirey-Rice JK, Aronoff DM. Pulley JM, et al. Among authors: zaleski nm. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:333-352. doi: 10.1146/annurev-pharmtox-010919-023537. Epub 2019 Jul 23. Annu Rev Pharmacol Toxicol. 2020. PMID: 31337270 Review.
Systematically Prioritizing Candidates in Genome-Based Drug Repurposing.
Challa AP, Lavieri RR, Lewis JT, Zaleski NM, Shirey-Rice JK, Harris PA, Aronoff DM, Pulley JM. Challa AP, et al. Among authors: zaleski nm. Assay Drug Dev Technol. 2019 Nov/Dec;17(8):352-363. doi: 10.1089/adt.2019.950. Epub 2019 Nov 26. Assay Drug Dev Technol. 2019. PMID: 31769998 Free PMC article.
Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases.
Challa AP, Zaleski NM, Jerome RN, Lavieri RR, Shirey-Rice JK, Barnado A, Lindsell CJ, Aronoff DM, Crofford LJ, Harris RC, Alp Ikizler T, Mayer IA, Holroyd KJ, Pulley JM. Challa AP, et al. Among authors: zaleski nm. Front Genet. 2021 Jul 28;12:707836. doi: 10.3389/fgene.2021.707836. eCollection 2021. Front Genet. 2021. PMID: 34394194 Free PMC article.
Walk before you run: Feasibility challenges and lessons learned from the PROCLAIM study, a multicenter randomized controlled trial of misoprostol for prevention of recurrent Clostridioides difficile during COVID-19.
Lavieri RR, Dubberke ER, McGill SK, Bartelt L, Smith SA, Pandur BK, Phillips SE, Vermillion K, Shirey-Rice J, Pulley J, Xu Y, Lindsell CJ, Zaleski N, Jerome R, Doster RS, Aronoff DM. Lavieri RR, et al. Anaerobe. 2023 Apr;80:102699. doi: 10.1016/j.anaerobe.2023.102699. Epub 2023 Jan 23. Anaerobe. 2023. PMID: 36702174 Free PMC article. Clinical Trial.
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Gentile N, Collins S, McCarthy MW, Jayaweera D, Castro M, Sulkowski M, McTigue K, Thicklin F, Felker GM, Ginde AA, Bramante CT, Slandzicki AJ, Gabriel A, Shah NS, Lenert LA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Wilder R, Wilson S, Shenkman E, Hernandez AF; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators. Naggie S, et al. JAMA. 2022 Oct 25;328(16):1595-1603. doi: 10.1001/jama.2022.18590. JAMA. 2022. PMID: 36269852 Free PMC article. Clinical Trial.
13 results